Latest News

Otsuka and Lundbeck Will Face Scrutiny Over Investigational PTSD Therapy at July 18 FDA AdComm Meeting
Otsuka and Lundbeck Will Face Scrutiny Over Investigational PTSD Therapy at July 18 FDA AdComm Meeting

July 17th 2025

FDA's Psychopharmacologic Drugs Advisory Committee will evaluate the novel brexpiprazole/sertraline combination, weighing efficacy against existing therapies amid mixed trial results.

Maternal Depression Impairs Emotional Responsiveness To, Daily Care For Infants, Children: Global Systematic Review / image credit  Tiago Munhoz, PhD   Courtesy of Federal University of Pelotas
Maternal Depression Impairs Parental Emotional Responsiveness, Daily Care for Infants, Children: Global Systematic Review

July 15th 2025

Investigational Rapid-Acting PTSD Medication Awarded FDA Breakthrough Therapy Status / image credit ©Feng Yu/stock.adobe.com
Investigational Rapid-Acting PTSD Medication Awarded FDA Breakthrough Therapy Status: Transcend Therapeutics Update

July 10th 2025

Phase 2b study of Psychedelic Compound BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression / image credit ©fyb/stock.adobe.com
Phase 2b Study of Psychedelic BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression

July 2nd 2025

Late Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals
Late-Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals

June 13th 2025

Latest CME Events & Activities

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Southern Florida Psychiatry Conference

November 21-22, 2025

Register Now!

Real Psychiatry 2026

January 23-24, 2026

View More

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

Optimizing Care for Patients With Tardive Dyskinesia

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

More News

© 2025 MJH Life Sciences

All rights reserved.